Amgen Inc (AMGN) 161.78 $AMGN Midday Glance:

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 1:31 PM

Amgen Inc (AMGN) 161.78 $AMGN

Midday Glance: Biotechnology companies
AP - 11 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - 2 hrs 26 mins ago
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.30 (+0.30), EW: 147.63 (+12.28), AMGN: 161.78 (+7.52), MBLY: 42.09 (+0.46), REGN: 446.44 (+17.06)

Early Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), AMGN: 161.78 (+7.52)

Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT

AMGN: 161.78 (+7.52), SNY: 48.70 (+1.63), REGN: 446.44 (+17.06)

1 Expensive Biotech Stock Worth Buying
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 15, 10:01AM CDT
Source: Ligand Pharmaceuticals Why buy something that's expensive? There are multiple answers to this question, of course. I'd contend that the best response of all is that it makes sense to buy an expensive item if its value is likely to...
AMGN: 161.78 (+7.52), LGND: 75.17 (+0.18), GSK: 46.91 (+0.54)

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha(TM) (evolocumab) In The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha(TM) (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trial to date (OSLER-1) was also presented.
AMGN: 161.78 (+7.52)

Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 419.99 (+6.64), ESRX: 83.50 (+2.13), GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), ABBV: 58.93 (+0.93), CELG: 120.02 (+2.29)

Japanese study shows Amgen's evolocumab lowers bad cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 8:17PM CDT

AMGN: 161.78 (+7.52)

New Detailed Data From Phase 3 Study Show Amgen's Repatha(TM) (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Sat Mar 14, 11:30AM CDT
Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha(TM) (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76 percent from baseline at week 12 and at the mean of weeks 10 and 12. The data were presented at the American College of Cardiology's 64th Annual Scientific Session (ACC.15).
AMGN: 161.78 (+7.52)

3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), IBB: 351.70 (+6.37), AMGN: 161.78 (+7.52)

Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.72 (+0.74), CLDX: 30.35 (+0.61), EPZM: 22.42 (-0.60), STML: 16.23 (+0.22), JNJ: 100.53 (+1.32), ABBV: 58.93 (+0.93), INFI: 16.05 (+0.59), PTLA: 41.44 (+0.74), INCY: 90.04 (+0.73), PFE: 34.45 (+0.45), IMGN: 7.66 (-0.19), AMGN: 161.78 (+7.52), LLY: 71.13 (+1.24), BMY: 67.86 (+0.99), GSK: 46.91 (+0.54), SGEN: 38.93 (+0.62), GILD: 100.94 (+1.33), KITE: 63.24 (+0.15), MRK: 57.05 (+0.85), TEVA: 60.60 (+0.60), CELGZ: 3.02 (-0.03), KPTI: 30.65 (+2.57), NVS: 97.93 (+0.89)

Amgen Has Been Flat For The Past 4 Months
Abba's Aces - at Seeking Alpha - Fri Mar 13, 8:39AM CDT

AMGN: 161.78 (+7.52)

Patient enrollment complete in trial expansion phase of Cytokinetics' heart drug
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:19AM CDT

CYTK: 7.73 (-0.25), AMGN: 161.78 (+7.52)

Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 64.94 (-0.09), AMGN: 161.78 (+7.52), AKBA: 12.86 (-0.38), AMAG: 54.52 (-0.48)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lavazza 2027 Calendar: Moments of Pleasure Worldwide

Capturing Fleeting Joy Through the Lens In 2027, Lavazza sets the stage for an evocative exploration of human pleasure through its iconic calendar. Teaming up with photographers Jim Goldberg, Alex Majoli, and Paolo Pellegrin, the project spans three vibrant cities: New York, Lisbon, and Hong Kong. These masters of the lens invite us to pause and appreciate the understated...

Endava Faces Class Action: Investor Reactions and Next Steps

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

Eve Air Mobility's Vector System Proves Its Worth

Eve Air Mobility's Vector system just pulled off something impressive at the Interlagos Circuit, showing it's not just a buzzword in the urban air mobility sphere. Picture this—over 100 helicopter flights in a day, all managed smoothly during one of the biggest motorsport events. That's the kind of action that gets investors to sit up and take notice of NYSE:EVEX....

Toronto's Distillery Winter Village Kicks Off 2026

Toronto's Holiday Spirit Ignites Toronto just cranked up the holiday spirit with the lighting of a 55-foot Christmas tree at The Distillery Winter Village. Let me tell you, it's a sight that could warm your innards on the coldest winter night. Presented by Quince, this winter wonderland opened its doors for 2026—and it's looking like they're pulling out all the stops...

New Senior Care Location Opens in Broward County

A Personal Mission Driving Business in Hollywood Dive deep into any community, and you'll often find stories that tug at the heartstrings—especially when they're about family. That's the case with Saudia Sital, a Broward County local who's just opened Always Best Care Senior Services in Hollywood, Florida. Her journey from personal caregiver to business owner isn't just...

Hebrew Learning Made Simple: Expert's Structured Guide

Cracking the Hebrew Code: A Balanced Guide Ever tried staring down a new language script and felt like you were on a sinking ship? That’s where a lot of folks starting off with Hebrew reading find themselves. It's no sunny stroll through a Greek alphabet park—Hebrew's a whole different ballgame. But Diana Yacobi from Sarah & David’s Read Hebrew Now offers a roadmap...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Dana-Farber Integrates IconPCR for Precise cfDNA Sequencing

Innovating Precision in cfDNA Sequencing One day you're trudging along old paths, and the next, technology throws you a curveball that's too critical to ignore. That's the scene at Dana-Farber Cancer Institute with their latest lab upgrade. They've bent the knee to integrate n6's iconPCR system into their toolkit for liquid biopsy research—a move that's caught my...

Sports Clock Radio: A Game Time Enthusiast's Dream

A New Gadget for the Diehard Fan Fanatics, gather 'round. There's an innovation rolling out that's looking to marry the good old alarm clock radio with the rush of game day fever! Over in Pittsburgh, an inventor's cooking up something that every loyal sports fan might soon find irresistible—a Sports Clock Radio, bringing the stadium experience to your living room or...

Cuisine.K Brings Korean Seafood to Seattle Spotlight

Korean Seafood Makes Waves in Seattle Bring out the chopsticks, ‘cause Korean seafood just took Seattle by storm with the Cuisine.K Korean culinary showcase. Hosted by CJ Foods, alongside the Korea Fisheries Association, this event smacked the local food scene square in the face with the unique flavors and techniques of K-Seafood—from students all the way to seasoned...